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Summary
Background Bivalirudin, with selective use of glycoprotein (GP) IIb/IIIa inhibitor agents, is an accepted standard of 
care in primary percutaneous coronary intervention (PPCI). We aimed to compare antithrombotic therapy with 
bivalirudin or unfractionated heparin during this procedure.
Methods In our open-label, randomised controlled trial, we enrolled consecutive adults scheduled for angiography in 
the context of a PPCI presentation at Liverpool Heart and Chest Hospital (Liverpool, UK) with a strategy of delayed 
consent. Before angiography, we randomly allocated patients (1:1; stratiﬁ ed by age [<75 years vs ≥75 years] and 
presence of cardiogenic shock [yes vs no]) to heparin (70 U/kg) or bivalirudin (bolus 0·75 mg/kg; infusion 
1·75 mg/kg per h). Patients were followed up for 28 days. The primary eﬃ  cacy outcome was a composite of all-cause 
mortality, cerebrovascular accident, reinfarction, or unplanned target lesion revascularisation. The primary safety 
outcome was incidence of major bleeding (type 3–5 as per Bleeding Academic Research Consortium deﬁ nitions). 
This study is registered with ClinicalTrials.gov, number NCT01519518.
Findings Between Feb 7, 2012, and Nov 20, 2013, 1829 of 1917 patients undergoing emergency angiography at our 
centre (representing 97% of trial-naive presentations) were randomly allocated treatment, with 1812 included in the 
ﬁ nal analyses. 751 (83%) of 905 patients in the bivalirudin group and 740 (82%) of 907 patients in the heparin group 
had a percutaneous coronary intervention. The rate of GP IIb/IIIa inhibitor use was much the same between groups 
(122 patients [13%] in the bivalirudin group and 140 patients [15%] in the heparin group). The primary eﬃ  cacy 
outcome occurred in 79 (8·7%) of 905 patients in the bivalirudin group and 52 (5·7%) of 907 patients in the heparin 
group (absolute risk diﬀ erence 3·0%; relative risk [RR] 1·52, 95% CI 1·09–2·13, p=0·01). The primary safety outcome 
occurred in 32 (3·5%) of 905 patients in the bivalirudin group and 28 (3·1%) of 907 patients in the heparin group 
(0·4%; 1·15, 0·70–1·89, p=0·59).
Interpretation Compared with bivalirudin, heparin reduces the incidence of major adverse ischaemic events in the 
setting of PPCI, with no increase in bleeding complications. Systematic use of heparin rather than bivalirudin would 
reduce drug costs substantially.
Funding Liverpool Heart and Chest Hospital, UK National Institute of Health Research, The Medicines Company, 
AstraZeneca, The Bentley Drivers Club (UK).
Introduction
Primary percutaneous coronary intervention (PPCI) has 
emerged as the optimum reperfusion strategy for 
patients presenting with acute myocardial infarction 
associated with ST segment elevation (STEMI).1,2 The 
optimum regimen for adjunctive anti thrombotic therapy 
in PPCI is unknown. Treatment at present is based on 
the combined use of both antiplatelet and antithrombotic 
drugs. In the procedural phase and beyond, some form 
of dual-agent, oral antiplatelet therapy is the accepted 
standard.1,2 Additional antiplatelet eﬀ ect can be obtained 
with the use of parenteral glycoprotein (GP) IIb/IIIa 
receptor antagonists.
The two most commonly used antithrombotic drugs 
are unfractionated heparin and bivalirudin. Two 
contemporary trials3,4 have compared these drugs in the 
PPCI setting. HORIZONS-AMI3 compared bivalirudin to 
a combination of heparin plus mandated GP IIb/IIIa 
inhibitors. In 2013, the EUROMAX study4 assessed 
antithrombin treatment started during trans port, 
comparing bivalirudin against either un fractionated or 
low molecular weight heparin. The trial design enshrined 
asymmetrical use of GP IIb/IIIa inhibitors, allowing 
routine or selective use with heparin (given in 
69% of cases) and only bailout use in the bivalirudin 
group (11·5% of cases).
Interpretation of this evidence base is complicated 
by use of outcomes that combine both efficacy and 
safety measures. Bleeding rates were increased by 
widespread administration of GP IIb/IIIa inhibitor. 
Stent thrombosis events were more common with 
bivalirudin therapy than with heparin therapy. 
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The relative safety and eﬃ  cacy of heparin and 
bivalirudin needed to be assessed in a study design 
representing modern PPCI practice. Our trial, How 
Eﬀ ective are Antithrombotic Therapies in Primary 
Percutaneous Coronary Intervention (HEAT-PPCI), 
was created with a pragmatic design. We reserved GP 
IIb/IIIa inhibitor drugs for selective bailout use as per 
the European Society of Cardiology (ESC) guidelines.1 
This approach sought to create a classic experiment, in 
which the two study groups (created at randomisation) 
were balanced except for the mutually exclusive 
therapies under assessment.
The study design also sought to address another 
common limitation of the randomised controlled trial; 
recruitment of only a modest proportion of the 
potential, eligible population. Such selective inclusion 
can restrict the generalisation of study ﬁ ndings in 
clinical practice. The mortality rate in HORIZONS-AMI3 
was less than half that declared by national registries 
and reported in individual centres. Very sick, elderly, or 
frail patients, those with low socioeconomic status, 
women, and individuals from ethnic minorities are 
often not approached for study participation.5 We 
obtained ethical approval for a policy of delayed consent 
and set ourselves the demanding goal to randomise all 
eligible patients entering the catheterisation laboratory 
in the setting of a PPCI activation—“Every Patient, 
Every Time”.
Methods
Study design and population
In this open-label, randomised controlled trial, we 
screened all patients who presented to the PPCI service 
at the Liverpool Heart and Chest Hospital (Liverpool, UK) 
during the recruitment period. We enrolled adults 
(≥18 years) unless they had known intolerance, 
hypersensitivity, or contraindication to any trial drug; 
active bleeding at presentation; artiﬁ cial ventilation, 
reduced conscious level or other factors precluding the 
administration of oral antiplatelet therapy; their physician 
refused to administer antiplatelet loading (uncertain 
diagnosis or risk of bleeding); or if they had previously 
been enrolled in this trial.
Full ethical approval was granted for the use of delayed 
consent. Patients were randomly allocated treatment 
and underwent angiography in an emergency setting 
and no attempt was made to discuss the trial or to seek 
consent during this phase. Surviving patients or their 
appropriate representatives (in 15 cases) were 
subsequently approached for formal consent to continue 
as trial participants, to use their data and to allow contact 
for the 28 day follow-up. STEMI has a high early hazard 
and a number of patients died after randomisation but 
before consent could be obtained. We obtained approval 
from the national Conﬁ dentiality Advisory Group to 
include the clinical data and outcome measures from 
these patients. The study protocol was approved by the 
National Research Ethics Service (North West, Liverpool 
East) and the UK Medicines and Healthcare Products 
Regulatory Agency.
Randomisation and masking
We randomly allocated participants (1:1) at presentation 
to the Liverpool Heart and Chest Hospital and before 
entry to the cardiac catheterisation laboratory, by use of 
a dedicated computer running a bespoke randomisation 
application as its sole software function. Patient 
2490 PPCI activations at the host institution during recruitment period
12 cases when pathway activated in error
101 other (non-PPCI) emergencies used pathway
36 cases did not arrive at PPCI centre
401 judged as incorrect activations (not STEMI)
23 suspected STEMI cases did not have angiography
1917 patients scheduled for emergency angiography
29 (2%) previous randomisation in the trial
59 (3%) met other exclusion criteria
42 had factors precluding DAPT (eg, ventilation)
9 cases physician refused to administer DAPT
7 had contraindication to DAPT or trial drugs
1 had active bleeding
1829 eligible for recruitment
1829 randomised in the trial
914 were assigned to receive heparin
900 (98%) received treatment as allocated
14 did not receive any trial medication
3 received LMWH preprocedure
7 died before consent
7 (1%) surviving patients have no
consent available
6 unable to get consent
1 withdrew consent
0 refused consent
907 follow up complete for index admission
2 (<1%) lost to follow up at 28 days
907 included in the analysis
915 were assigned to receive bivalirudin
907 (99%) received treatment as allocated
1 received heparin only
7 did not receive any trial medication
4 received LMWH preprocedure
10 died before consent
10 (1%) surviving patients have no 
consent available
7 unable to get consent
0 withdrew consent
3 refused consent
905 follow up complete for index admission
0 lost to follow up at 28 days
905 included in the analysis
Figure 1: Trial proﬁ le 
PPCI=primary percutaneous coronary intervention. STEMI=ST-elevation myocardial infarction. DAPT=dual 
antiplatelet therapy. LMWH=low molecular weight heparin.
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registration was required before release of the treatment 
allocation. Randomisation was stratiﬁ ed by age 
(<75 years vs ≥75 years) and by the presence or absence 
of cardiogenic shock. Randomisation tables were 
prepared independent of the clinical staﬀ . An 
emergency backup option was provided in the event of 
computer failure. This backup was based on the 
sequential use of serial numbered, opaque envelopes, 
separated into four distinct groups reﬂ ecting the 
stratiﬁ cation options. We used random variation of 
block sizes of 2, 4, and 6, except for patients with 
cardiogenic shock and those randomly allocated 
Bivalirudin group (n=905) Heparin group (n=907)
Age, years 62·9 (53·7–74·0) 63·6 (54·0–73·8)
Sex, female 258/905 (29%) 244/907 (27%)
Race, white 866/904 (96%) 870/907 (96%)
Bodyweight, kg
Data available 818 (90%) 813 (90%)
Median 80 (67–90) 80 (70–90)
Comorbidities
Diabetes 114/902 (13%) 136/899 (15%)
Hypertension 362/902 (40%) 388/903 (43%)
Hyperlipidaemia 327/893 (37%) 342/899 (38%)
Family history of cardiovascular disease 388/891 (44%) 401/894 (45%)
Current smoker 371/888 (42%) 379/888 (43%)
Previous myocardial infarction 122/903 (14%) 93/906 (10%)
Previous PCI 76/903 (8%) 54/904 (6%)
Previous coronary artery bypass graft 22/903 (2%) 20/906 (2%)
Symptom onset to randomisation time, h
Data available 896 (99%) 891 (98%)
Median 2·8 (1·7–5·5) 2·7 (1·5–5·3)
Blood tests on admission
Platelet count
Data available 886 (98%) 889 (98%)
Median 229 (186–275) 223 (186–266)
Estimated glomerular ﬁ ltration rate
Data available 836 (92%) 850 (94%)
Median 80 (64–90) 80 (65–90)
Haemoglobin
Data available 891 (98%) 895 (99%)
Median 13·6 (12·4–14·6) 13·7 (12·5–14·7)
Aspirin use 899/905 (99%) 905/906 (100%)
P2Y12 inhibitor loading dose
Any drug 901/905 (>99%) 902/907 (99%)
Clopidogrel 107/905 (12%) 91/907 (10%)
Prasugrel 247/905 (27%) 250/907 (28%)
Ticagrelor 554/905 (61%) 569/907 (63%)
Glycoprotein IIb/IIIa inhibitor use 122/905 (13%) 140/906 (15%)
Arterial access site
Femoral 171/905 (19%) 161/907 (18%)
Radial 727/905 (80%) 744/907 (82%)
Activated clotting time, s
5–15 min after bolus dose
Data available 806 (89%) 795 (88%)
Median 251 (229–285) 224 (200–256)
At the end of the procedure
Data available 771 (85%) 777 (86%)
Median 246 (229–270) 206 (188–229)
(Table 1 continues on next page)
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according to sealed envelope, in which the block 
sizes were 2 and 4.
Procedures
All patients received dual antiplatelet therapy before PPCI 
as per routine practice at the host institution and its 
referring emergency departments. After entry to the 
catheter laboratory, and before the angiographic ﬁ ndings 
were known, patients received the assigned drug. Heparin 
was given as a bolus dose of 70 U/kg bodyweight before the 
procedure. Additional doses were administered if activated 
clotting time values 5–15 min after the bolus dose or at the 
end of the procedure were less than 200 s. Bivalirudin was 
given as a bolus of 0·75 mg/kg followed by infusion of 
1·75 mg/kg per h for the duration of the procedure. A 
rebolus of 0·3 mg/kg was administered if activated clotting 
time values 5–15 min after the bolus dose or at the end of 
the procedure were less than 225 s. We monitored activated 
clotting time with Actalyke XL MAX-ACT system (Helena 
Laboratories, Beaumont, TX, USA). The GP IIb/IIIa 
inhibitor, abciximab, was allowed for selective use in both 
groups as per the European Society of Cardiology 
guidelines (with angio graphic evidence of massive 
thrombus, slow or no-reﬂ ow, or a thrombotic 
complication).1 The recommended dose was 0·25 mg/kg 
intravenous bolus, followed by a continuous intravenous 
infusion of 0·125 μg/kg per min (to a maximum of 
10 μg/min) for 12 h. No other trial-related restrictions were 
imposed on the performance of angiography and PCI, 
which were done in accordance with prevailing best local 
practice as determined by the attending inter ventional 
cardiologist. Blood sampling was done 12–18 h after the 
index procedure to assess creatinine kinase (CK)-MB 
concentration in patients with a suspected or proven 
diagnosis of myocardial infarction.
Patient case notes and electronic records were 
examined by the trial investigators, throughout the 
course of the index admission, to allow contemporaneous 
completion of the trial-speciﬁ c case record forms. All 
patients were followed up for 28 days.
Bivalirudin group (n=905) Heparin group (n=907)
(Continued from previous page)
Managed with PCI* 751/905 (83%) 740/907 (82%)
Thrombectomy 444/751 (59%) 426/740 (58%)
Single-vessel treated 700/751 (93%) 668/740 (90%)
Main culprit lesion treated with primary PCI
Left main stem 7/751 (1%) 7/740 (1%)
Left anterior descending artery 304/751 (40%) 298/740 (40%)
Left circumﬂ ex coronary artery 99/751 (13%) 109/740 (15%)
Right coronary artery 333/751 (44%) 324/740 (44%)
Bypass graft 8/751 (1%) 2/740 (<1%)
Balloon angioplasty only 51/751 (7%) 42/740 (6%)
Implantation of stent
Any type 697/751 (93%) 682/740 (92%)
Drug eluting 599/751 (80%) 591/740 (80%)
TIMI III ﬂ ow
Before PCI 88/751 (12%) 79/740 (11%)
After PCI 701/751 (93%) 686/740 (93%)
Left ventricular function after index event 832/903 (92%) 835/906 (92%)
Normal (ejection fraction ≥55%) 365/832 (44%) 379/835 (45%)
Mildly impaired (ejection fraction 45–54%) 218/832 (26%) 210/835 (25%)
Moderately impaired (ejection fraction 36–44%) 165/832 (20%) 168/835 (20%)
Severely impaired (ejection fraction ≤35%) 84/832 (10%) 78/835 (9%)
Medications at discharge
ACE inhibitor or ARB 707/842 (84%) 725/844 (86%)
Aspirin 788/842 (94%) 799/844 (95%)
β blocker 728/842 (86%) 731/844 (87%)
P2Y12 inhibitor 748/842 (89%) 746/844 (88%)
Statin 761/842 (90%) 767/844 (91%)
Data are median (IQR), n/n assessed (%), or n (%). PCI=percutaneous coronary intervention. TIMI=thrombolysis in myocardial infarction. ACE=angiotensin-converting 
enzyme. ARB=angiotensin II receptor blocker. *In patients managed with PCI, 116 (15%) of 751 patients in the bivalirudin group and 136 (18%) of 740 patients in the heparin 
group received glycoprotein IIb/IIIa inhibitors.
Table 1: Baseline characteristics, procedural data, and drug use 
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We monitored all study primary and secondary 
outcome measures against the host institution’s clinical 
coding department records. We did quarterly audits 
against data collected by hospital clinical audit depart-
ment to crosscheck the fate of all PPCI activations for the 
host institution. Patient reports were also crosschecked 
against national mortality data tracking and Hospital 
Episode Statistics—a national group that records all 
hospital admission events in the UK, including 
diagnostic and procedural coding.
All primary eﬃ  cacy and safety outcome measures and 
stent thrombosis events were assessed by an independent 
Clinical Events Committee. The members of this 
committee were masked to treatment group allocation. A 
data monitoring and safety committee had access to all 
aspects of the trial management structure, clinical data, 
and administrative documentation. The data monitoring 
and safety committee did a site visit and inspection after 
900 patients had been randomised and did one 
subsequent, interim safety analysis of unmasked data. 
They recommended that recruitment should continue to 
the original target.
Outcomes
The primary eﬃ  cacy outcome was the proportion of 
patients who had at least one major adverse cardiac event 
(MACE) at 28 days. MACE was a composite of all-cause 
mortality, cerebrovascular accident, reinfarction, or 
additional unplanned target lesion revascularisation. The 
primary safety outcome was the proportion of patients 
who had major bleeding by 28 days, classiﬁ ed as type 3–5 
according to the Bleeding Academic Research Con-
sortium (BARC) deﬁ nition. Key secondary outcome 
measures included stent thrombosis rates, cardiac 
enzyme release, and minor bleeding (BARC type 2). The 
appendix provides full deﬁ nitions of the study outcomes. 
Prespeciﬁ ed subgroup analyses included assessment of 
the primary outcome according to the route of arterial 
vascular access, left ventricular function, age, history of 
diabetes, type of P2Y12 inhibitor used, and whether or 
not PCI was attempted.
Statistical analysis
In HORIZONS-AMI,3 the 30 day MACE rate was 5·5%. 
Because our study would include all patients, including 
high-risk presentations, we estimated a MACE rate of 
7·5%. Our statistical approach used an established 
method.6 We used two-sided testing to allow rejection of 
the null hypothesis in favour of either therapy. We used 
the χ² test comparison of proportions to compare the 
primary safety and eﬃ  cacy outcome measures. We 
established prespeciﬁ ed criteria for the declaration of 
treatment equivalence. We considered the absolute 
diﬀ erence in the observed event rates between the two 
treatment arms. Equivalence would be assumed if the 
point estimate lay in the range ±0·5% from the zero 
diﬀ erence point. Assuming an identical event rate at 
7·5%, a sample size of 1800 patients would, within the 
upper boundary of a two-sided 95% CI, allow the exclusion 
of a 2·5% absolute diﬀ erence in event rates.
We did all analyses according to intention to treat and 
patient data are reported and analysed in the two trial 
groups as allocated at randomisation. We regarded 
diﬀ erences as signiﬁ cant with a maximal type I error risk 
of 5%. We compared categorical data with the χ² test (or 
Fisher’s exact test when the absolute number of observed 
events in any group was ﬁ ve or less). We compared 
continuous data with the t test (or the Wilcoxon test in 
the case of non-normal data). Data analyses were done by 
two statisticians, independent of the HEAT-PPCI 
research team. All statistical analyses were done with 
SAS software, version 9.3. This study is registered with 
ClinicalTrials.gov, number NCT01519518.
Role of the funding source
The study was partially funded by unrestricted grants 
from The Medicines Company and AstraZeneca but 
these companies had no involvement in any aspect of 
Bivalirudin group (n=905) Heparin group (n=907)
Hierarchy* All events Hierarchy* All events
Primary eﬃ  cacy outcomes
Death 46 (5·1%) 46 (5·1%) 39 (4·3%) 39 (4·3%)
Cerebrovascular accident 11 (1·2%) 15 (1·7%) 6 (0·6%) 11 (1·2%)
New myocardial infarction or reinfarction 21 (2·3%) 24 (2·7%) 7 (0·8%) 8 (0·9%)
Additional unplanned target lesion revascularisation 1 (0·1%) 24 (2·7%) 0 6 (0·7%)
Total events 79 (8·7%) 109 (12·0%) 52 (5·7%) 64 (7·0%)
Bleeding outcomes
Major bleed 32 (3·5%) 32 (3·5%) 28 (3·1%) 28 (3·1%)
Minor bleed 81 (9·0%) 83 (9·2%) 94 (10·4%) 98 (10·8%)
Total events 113 (12·5%) 115 (12·7%) 122 (13·5%) 126 (13·9%)
Data are n (%). *Censored by most severe event in the order speciﬁ ed.
Table 2: Hierarchical outcomes 
See Online for appendix
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trial design, conduct, or reporting. All authors have had 
access to the trial data. AS and RHS (the principal 
investigator) had full responsibility for the decision to 
submit, for the accuracy and completeness of the data, 
and for all analyses.
Results
Between Feb 7, 2012, and Nov 20, 2013, the PPCI pathway 
system was activated at the host institution on 
2490 occasions. 1917 (77%) patients were scheduled for 
emergency angiography for a suspected STEMI event, 
and were eligible for randomisation (ﬁ gure 1). 
29 (2%) patients were already enrolled in the trial and a 
59 (3%) met one or more exclusion criteria. Thus 
1829 patients were randomly allocated treatment. 
Eight (<1%) patients were randomly allocated with 
envelope randomisation. 14 (2%) patients in the heparin 
group and seven (1%) patients in the bivalirudin group 
did not receive any trial medication. One patient 
randomly allocated bivalirudin received heparin alone. 
17 (1%) patients died before the investigators were able 
to obtain consent (seven in the heparin group, ten in the 
bivalirudin group). Consent was not available for a 
further 17 surviving patients (13 contact lost before 
consent, one withdrawal and three refusals). These 
patients have been excluded from the analyses but we 
know, from national mortality tracking, that all were alive 
at 28 days after their randomisation. All surviving 
patients were followed up for 28 days with direct contact 
at that time. 47 participants remained inpatients at 
28 days in the context of their index admission. Of the 
remainder, 1595 patients responded to a structured 
request for information by post, telephone, email, or text 
messaging. 95 patients reported their status at a 
subsequent routine care medical consultation. For two 
patients, we used information from UK mortality 
tracking, and Hospital Episode Statistics. A further two 
patients were tracked for the complete duration of their 
index admission but have no follow-up after hospital 
discharge and to 28 days. These patients have been 
included in the analyses.
The baseline characteristics of patients were well 
matched between the two groups included in the analyses 
apart from increased rates of patient-reported previous 
myocardial infarction and PCI in the bivalirudin group 
(table 1).
Aspirin and P2Y12 inhibitor loading was achieved in 
more than 99% of patients and PPCI was completed with 
exclusive radial access in about 80% of cases (table 1). 
Activated clotting time values, measured during the 
procedure, were as expected for both heparin and 
bivalirudin therapy (appendix). GP IIb/IIIa inhibitor use 
did not diﬀ er between groups (table 1). The main reasons 
for GP IIb/IIIa inhibitor use, reported by the operator, 
were the presence of high intracoronary thrombus 
burden (82 [73%] in the bivalirudin group vs 94 [67%] in 
the heparin group), slow ﬂ ow (19 [17%] vs 21 [15%]), 
perceived failure of antiplatelet loading (eg, with 
vomiting; seven [6%] vs nine [6%]), and complex lesion or 
stent placement (seven [6%] vs four [3%]). Post-procedure 
left ventricular ejection fraction did not diﬀ er between 
groups (table 1).
Percutaneous coronary intervention was attempted in 
1491 (82%) patients with much the same procedural 
success in both groups (732 [97·5%] of 751 procedures in 
the bivalirudin group vs 720 [97·3%] of 740 procedures in 
the heparin group). More than 90% of these patients had 
a stent implanted (table 1). Thrombus aspiration was 
done in almost 60% of patients in both groups (table 1).
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Figure 2: Event curves for the primary outcomes
(A) Primary eﬃ  cacy outcome (combination of death, cerebrovascular accident, reinfarction, and unplanned target 
lesion revascularisation), censored for the ﬁ rst event. (B) Primary safety outcome (major bleeding), censored for 
the ﬁ rst event.
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The contribution of the individual components to the 
primary eﬃ  cacy outcome is shown in table 2. Events 
have been censored by the most severe event in the 
observation period. Only one event accrued from an 
unplanned target lesion revascularisation in the absence 
of another outcome event. Figure 2 shows the event 
curves for the primary eﬃ  cacy and safety outcome 
measures for both treatment groups.
For the primary outcome, at least one MACE occurred 
in 79 (8·7%) of 905 patients in the bivalirudin group and 
52 (5·7%) of 907 patients in the heparin group 
(absolute risk diﬀ erence 3·0%; relative risk [RR] 1·52, 
95% CI 1·09–2·13, p=0·01). We noted the advantage of 
heparin therapy in all components of the primary eﬃ  cacy 
outcome but no signiﬁ cant diﬀ erences in the individual 
components of incidence of all-cause mortality or 
cerebrovascular accident (table 3). The heparin advantage 
was primarily driven by a signiﬁ cant increase in the 
incidence of reinfarction in the bivalirudin group 
(ﬁ gure 3). Most of these events were related to stent 
thrombosis events, which were more frequent in the 
bivalirudin group than the heparin group (table 3) and all 
but one reinfarction event was substantiated by 
angiographic ﬁ ndings. Stent thromboses were 
adjudicated as deﬁ nite in 28 (93%) of 30 cases, all of 
which resulted in an adjudicated reinfarction event and 
unplanned target lesion revascularisation.
For the primary safety outcome, major bleeding 
(BARC type 3–5) occurred in 32 (3·5%) of 905 patients in 
the bivalirudin group and 28 (3·1%) of 907 patients in the 
heparin group (absolute risk diﬀ erence 0·4%; 
relative risk [RR] 1·15, 95% CI 0·70–1·89, p=0·59; 
table 3). Rates of minor bleeding (BARC type 2) and the 
combined rate of major or minor bleeding events did not 
diﬀ er between groups (table 3).
Incidence of thrombocytopenia, median CK-MB 
release after procedure, and median door to ﬁ rst device 
time did not diﬀ er between groups (table 3). Prespeciﬁ ed 
subgroups analyses were consistent with those in the 
overall intention-to-treat analyses (ﬁ gure 3).
Discussion
To our knowledge, HEAT-PPCI is the only large trial of 
antithrombotic therapy in PPCI to have achieved near 
100% recruitment of all eligible patients. Our study 
population represented 97% of all patients who were 
managed with angiography at the study centre in the 
context of a PPCI presentation. We showed that use of 
heparin, rather than bivalirudin, confers signiﬁ cant 
advantage in the avoidance of major adverse events—
principally acute stent thrombosis and associated 
reinfarction events, with no diﬀ erence in bleeding.
Our approach allowed us to recruit a real-world, 
unselected population in a high volume UK centre. 
Bivalirudin group
(n=905)
Heparin group
(n=907)
Absolute risk diﬀ erence
(95% CI)
Relative risk
(95% CI)
p value
Primary eﬃ  cacy outcomes measures 79/905 (8·7%) 52/907 (5·7%) 3·0 (0·6 to 5·4) 1·52 (1·09 to 2·13) 0·01
Death 46/905 (5·1%) 39/907 (4·3%) 0·8 ( to 1·2 to 2·8) 1·18 (0·78 to 1·79) 0·43
Cerebrovascular accident 15/905 (1·6%) 11/907 (1·2%) 0·4 ( to 0·7 to 1·6) 1·37 (0·63 to 2·96) 0·43
New myocardial infarction or reinfarction 24/905 (2·7%) 8/907 (0·9%) 1·8 (0·6 to 3·1) 3·01 (1·36 to 6·66) 0·004
Additional unplanned target lesion revascularisation 24/905 (2·7%) 6/907 (0·7%) 2·0 (0·8 to 3·3) 4·01 (1·65 to 9·76) 0·001
Bleeding outcomes
Major bleed (primary safety outcome measure)* 32/905 (3·5%) 28/907 (3·1%) 0·4 ( to 1·2 to 2·1) 1·15 (0·70 to 1·89) 0·59
Minor bleed† 83/905 (9·2%) 98/907 (10·8%) –1·6 (–4·4 to 1·1) 0·85 (0·64 to 1·12) 0·25
Any bleeding event 113/905 (12·5%) 122/907 (13·5%) –1·0 (–4·1 to 2·1) 0·93 (0·73 to 1·18) 0·54
Other secondary outcome measures
Stent thrombosis rate 24/697 (3·4%) 6/682 (0·9%) 2·6 (1·0 to 4·3) 3·91 (1·61 to 9·52) 0·001
Deﬁ nite 23/697 (3·3%) 5/682 (0·7%) 2·6 (1·1 to 4·2) 4·50 (1·72 to 11·77) 0·001
Probable 1/697 (0·1%) 1/682 (0·1%) 0·0 (–0·7 to 0·7) 0·98 (0·06 to 15·6) >0·99
Acute (≤24 h) 20/697 (2·9%) 6/682 (0·9%) 2·0 (0·6 to 3·6) 3·26 (1·32 to 8·07) 0·007
Subacute (>24 h to 28 days) 4/697 (0·6%) 0/682 (0·0%) 0·6 (–0·9 to 1·5) 8·81 (0·48 to 163·26)‡ 0·12
Thrombocytopenia rate 61/736 (8·3%) 54/737 (7·3%) 1·0 (–1·8 to 3·7) 1·13 (0·80 to 1·61) 0·49
Mild 55/736 (7·5%) 48/737 (6·5%) 1·0 (–1·7 to 3·6) 1·15 (0·79 to 1·67) 0·47
Moderate 3/736 (0·4%) 5/737 (0·7%) –0·3 (–1·2 to 0·6) 0·60 (0·14 to 2·50) 0·73
Severe 3/736 (0·4%) 1/737 (0·1%) 0·3 (–0·4 to 1·1) 3·00 (0·31 to 28·81) 0·37
CK-MB post-procedure, ng/mL§ 97 (42 to 199) 106 (42 to 203) ·· ·· 0·55
Door to ﬁ rst device time, min¶ 29 (23 to 36) 29 (23 to 37) ·· ·· 0·33
CK=creatinine kinase. *Type 3–5 bleeding according to Bleeding Academic Research Consortium (BARC) deﬁ nition. †Type 2 bleeding according to BARC deﬁ nition. ‡Relative risk is relative to 0; SAS software has 
used a correction of 0·5 instead of 0 to generate a result. §CKMB reference range at the host institution was 0–4·9 ng/mL; 748 patients in the bivalirudin group and 733 patients in the heparin group. 
¶740 patients in the bivalirudin group and 728 patients in the heparin group.
Table 3: Clinical outcomes at 28 days
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Recruitment was done in less than 22 months. The 
strategy of delayed consent was well received by patients: 
refusal or withdrawal of consent was very rare 
(four cases).
Our study has strong internal validity but some 
limitations related to single-centre recruitment. Our 
patient population was 95% white (compared with a 2012 
UK PCI registry norm of 92%), but otherwise typical for 
UK practice. The near complete inclusion of a population 
selected by external referral (ambulance and emergency 
medical teams) was reassuring. The study examined the 
use of intravascular drugs and used accepted, 
standardised approaches to dosing and administration. 
Procedures were done under the care of 14 interventional 
cardiologists. Procedural detail and subsequent outcomes 
matched institutional and national norms and seem to 
reﬂ ect contemporary PPCI practice.
We used an open-label design but the outcome 
measures were overt clinical events, supported by 
objective clinical observations, even in the case of 
reinfarction. All events were subject to masked 
assessment. An open-label design was also used in the 
HORIZONS-AMI and EUROMAX trials.3,4
Heparin was administered at a dose of 70 U/kg of 
bodyweight. This strategy avoids the increased bleeding 
complications associated with the use of higher doses,7 
although some centres do use a more stringent regime at 
50 U/kg. Bivalirudin dosing was in accordance with the 
licensed recommendations at trial initiation, which 
included cessation of the infusion at the end of the 
procedure.
A PCI procedure was done in 82% of cases. This rate is 
lower than that in similar trials (93% in HORIZONS-AMI) 
but is representative of our intention-to-treat design. One 
alternative would be to delay randomisation until the 
angiographic ﬁ ndings are known—an approach that has 
a number of disadvantages. Patients might be treated 
with additional antithrombotic drugs, which are not trial 
speciﬁ ed, to facilitate the safe performance of 
angiography. The enthusiasm of an operator to recruit 
for the study might be aﬀ ected by knowledge of the 
coronary anatomy and the potential diﬃ  culty and 
duration of any proposed PCI procedure. We also believe 
that our methods reﬂ ect present and evolving best 
practice. We aim to provide optimum therapy, as 
evidenced by our favourable door-to-device time, which 
required prompt concurrent activity by all staﬀ  groups. 
The anticoagulant (in this case the trial drug) was often 
administered by our nursing team soon after arrival in 
the laboratory areas while the operator was securing 
arterial access.
Our primary eﬃ  cacy analysis suggests a signiﬁ cant 
advantage in favour of heparin over bivalirudin, mainly 
in terms of a reduced incidence of acute stent thrombosis 
and associated recurrent myocardial infarction. This 
ﬁ nding is consistent with the ﬁ nding of a signiﬁ cant 
increase in acute stent thrombosis, associated with 
bivalirudin therapy, in both HORIZONS-AMI 
Bivalirudin (n=905) Heparin (n=907) Relative risk (95% CI) pinteraction
All patients
Arterial access site*
Radial
Femoral
Diabetes†
Yes
No
Age (years)
≥75
<75
P2Y12 drug used
Clopidogrel
Prasugrel
Ticagrelor
Left ventricular function impaired‡
Yes
No
PCI attempted
Yes
No
 79/905 (8·7%)
 55/727 (7·6%)
 20/171 (11·7%)
 17/96 (17·7%)
 60/806 (7·4%)
 30/203 (14·8%)
 49/702 (7·0%)
 11/107 (10·3%)
 17/247 (6·9%)
 48/554 (8·7%)
 46/467 (9·9%)
 11/365 (3·0%)
 63/751 (8·4%)
 16/154 (10·4%)
 52/907 (5·7%)
 36/744 (4·8%)
 16/161 (9·9%)
 9/113 (8·0%)
 38/786 (4·8%)
 27/200 (13·5%)
 25/707 (3·5%)
 7/91 (7·7%)
 9/250 (3·6%)
 35/569 (6·2%)
 35/456 (7·7%)
 7/379 (1·9%)
 40/740 (5·4%)
 12/167 (7·2%)
1·52 (1·09–2·13)
1·56 (1·04–2·35)
1·18 (0·63–2·19)
2·22 (1·04–4·76)
1·54 (1·04–2·28)
1·09 (0·68–1·77)
1·97 (1·23–3·16)
1·34 (0·54–3·31)
1·91 (0·87–4·21)
1·41 (0·93–2·14)
1·28 (0·84–1·95)
1·63 (0·64–4·16)
1·55 (1·06–2·28)
1·45 (0·71–2·96)
0·48
0·35
0·11
0·78
0·67
0·88
Favours bivalirudin Favours heparin
1·0 2·0 3·0 5·00·1 0·2 0·3 0·5 10·0
Figure 3: Subgroup analyses for primary composite outcome at 28 days
*Procedures completed exclusively via radial access (radial group) versus all other cases (femoral group). †Patients receiving oral hypoglycaemic or insulin therapy. 
‡Left ventricular ejection fraction <55% in surviving patients after index event.
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(1·3% in the bivalirudin group vs 0·3% in the heparin 
group; p<0·001) and EUROMAX (1·1% vs 0·2%; 
p=0·007). The absolute stent thrombosis rate was higher 
in our study than it was in HORIZONS-AMI, which 
might be because of the high-risk population (28 day 
mortality 4·7% in this study vs 2·6% in HORIZONS-AMI). 
The magnitude of the diﬀ erence might also be because 
patients given bivalirudin were not protected by 
additional administration of heparin, which was reported 
in 65% of HORIZONS-AMI patients randomised to 
bivalirudin.8 Bivalirudin has been assessed against 
heparin in various clinical settings and indications in the 
past 20 years and has never established any clear 
advantage in terms of anti-ischaemic eﬃ  cacy.4,7;9–12
Both bivalirudin and heparin can be used in 
combination with GP IIb/IIIa inhibitor drugs. In the 
ACUITY trial9 (examining PCI in the context of non-ST 
elevation acute coronary syndrome events), both 
antithrombotic agents were employed with mandated 
GP IIb/IIIa therapy and the outcomes in terms of 
anti-ischaemic eﬃ  cacy and bleeding were near identical. 
Reduced bleeding was noted in a third trial arm testing 
bivalirudin with selective use of the parenteral 
antiplatelet drug.
Most evidence in PPCI has been obtained by 
comparing bivalirudin monotherapy with a combination 
of heparin plus GP IIb/IIIa inhibitors. In the acute 
phase, the reported advantages of bivalirudin are 
restricted to reduced bleeding complications which, in 
the HORIZONS-AMI trial,3 might have aﬀ ected 
medium-term mortality. Increased bleeding com-
plications are probably related to the diﬀ erential rates 
of GP IIb/IIIa inhibitors use. The universal, unselected 
use of GP IIb/IIIa inhibitors in PPCI is no longer 
routine therapy. The advent of more eﬀ ective oral 
antiplatelet therapy, with early and high dose-loading 
regimes might have reduced any incremental 
anti-ischaemic protection with GP IIb/IIIa inhibitors, 
while retaining the potential for bleeding complications. 
Public health and other measures mean that patients 
undergoing PPCI are treated early in the natural history 
of infarct evolution, when fresh thrombus might be 
easier to manage with interventional approaches. 
Technical advances, including a possible eﬀ ect from 
thrombus aspiration might also play a part.13,14 The 
ﬁ ndings at angiography, the response to intervention, 
and the perceived outcome of the PCI procedure could 
allow operators to identify patients who have most to 
gain from the addition of parenteral antiplatelet 
therapy. By the same token, bleeding risk can be avoided 
in patients with a good result or in those with risk 
factors from this complication. The optimum use 
pattern for GP IIb/IIa inhibitor agents is yet to be 
determined.
Bivalirudin with selective GP IIb/IIa inhibitor use has 
emerged as ﬁ rst-line therapy in the performance of 
PPCI. Our study builds on this evidence base and 
suggests that the use of heparin, rather than bivalirudin 
confers signiﬁ cant advantage in the avoidance of major 
adverse events. This ﬁ nding might provide an 
opportunity, rare in modern health care, to provide 
improved outcomes at much reduced cost. In our centre, 
routine use of heparin (rather than bivalirudin, which 
costs about 400 times as much) would reduce immediate 
drug costs in our annual 1000 PPCI cases by £500 000.
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Panel: Research in context
Systematic review
We searched PubMed, Medline, Scopus, ClinicalTrials.gov, and ISRCTN.org for any studies 
published in English comparing unfractionated heparin and bivalirudin in a primary 
percutaneous coronary intervention (PCI) setting. Our search terms were “bivalirudin”, 
“heparin”, “primary PCI”, “primary percutaneous coronary intervention”, “primary 
angioplasty”, and “STEMI”. Two randomised controlled trials were identiﬁ ed. The ﬁ rst trial, 
HORIZONS-AMI,3 compared bivalrudin against a combination of heparin and 
glycoprotein (GP) IIb/IIIa inhibitors. In the other trial, EUROMAX,4 GP IIb/IIIa inhibitors were 
used routinely in the heparin group and as bailout in the bivalirudin group. Both trials 
reported primary outcome measures that included rates of bleeding, which are usually 
regarded as a safety outcome in trials of antithrombotic therapy. Adverse event rates were 
lower with bivalirudin therapy than heparin therapy. This reduction was mainly driven by an 
increased incidence of major bleeding in the patients that received heparin and universal or 
routine GP IIb/IIIa inhibitors. Both trials also reported a signiﬁ cantly higher incidence of 
acute stent thrombosis in the bivalirudin group than the heparin group.
Interpretation
Bivalirudin with bailout use of GP IIb/IIIa inhibitors has become an established treatment 
option. To our knowledge, this treatment option has never been tested against heparin 
with bailout use of GP IIb/IIIa inhibitors. We know from many studies examining both 
heparin and bivalirudin that increased use of GP IIb/IIIa inhibitors results in increased 
bleeding. The relative eﬃ  cacy and safety of bivalirudin and heparin cannot be assessed 
reliably in studies with diﬀ erential use of GP IIb/IIIa inhibitors. An exploration of incidence of 
acute stent thrombosis with bivalirudin therapy in the setting of modern clinical practice 
was also needed. To our knowledge, HEAT-PPCI is the ﬁ rst randomised controlled trial to do 
a head-to-head comparison of heparin and bivalirudin in the setting of primary PCI with 
bailout use of GP IIb/IIIa inhibitors in both groups. By use of a strategy of delayed consent, 
the trial involved consecutive enrolment of an unselected population seeking to reﬂ ect 
real-world, contemporary practice. HEAT-PPCI showed a signiﬁ cant reduction in major 
adverse cardiac events (MACE) in favour of heparin. This ﬁ nding is related to an increased 
rate of acute stent thrombosis and associated reinfarction with bivalirudin therapy. We 
noted no signiﬁ cant diﬀ erence in bleeding complications between the two groups.
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